What's Hot
View all perspectives
Dr. Antoni Chan synovialjoints
1 year 5 months ago
Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG
Aurelie Najm AurelieRheumo
1 year 5 months ago
Prediction of RA early arthritis & clinically suspect arthralgia pts w/ AI analysis of MRIs scans:
✔️Feasible
✔️Accurate AUC 0.683 EA group AUC 0.727 CSA group
✔️Peformance = human experts
✚ Could identify new imaging biomarkers
https://t.co/sVXw9A8NqZ OP0002 #EULAR23 @Rheumnow https://t.co/oq5RJApm9U
Aurelie Najm AurelieRheumo
1 year 5 months ago
🚨EULAR PtC clinical & imaging features suspicious for progression to PsA
Main take home messages ⬇️⬇️
Obesity, Nail Disease, Extensive PsO, Arthralgia, US detected synovio-entheseal
involvement/abnormalities in US = risks factors of developing PsA in PsO pts.
@Rheumnow #EULAR23
Aurelie Najm AurelieRheumo
1 year 5 months ago
Provan et al. large scandinavian registry study: 🫁ILD risk in RA & PsA initiating b/tsDMARDs
HR ILD RA=10
HR ILD PsA=5
No increase risk w/ MTX and b/tsDMARDs but RA HR ILD 1.7 RTX vs. ETA: confounding by indication?
https://t.co/CF1ysNkQxU OP0006 #EULAR23 @Rheumnow https://t.co/DgDE1uFeUs
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 5 months ago
#EULAR2023 #OP0051 4-year Pooled Analyses of 3 x Anifrolumab RCTs in #lupus (inc. LTE) showed:
- LLDAS was attained earlier & more cumulative time was spent in LLDAS in anifrolumab compared to placebo groups
Assuring longer-term data
*sorry photos weren’t permitted @RheumNow
David Liew drdavidliew
1 year 5 months ago
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
Aurelie Najm AurelieRheumo
1 year 5 months ago
https://t.co/0FsCCOP17E OP0044 #EULAR23 @RheumNow https://t.co/pl0AnGUAw1
Aurelie Najm AurelieRheumo
1 year 5 months ago
Scandinavian RA registry study shows reassuring data on CV risk in RA🫀
Acute Coronary Syndrom incidence rates are similar in RA pts achieving remission & general pop & is similar whether RA pts reach remission using MTX or TNFi.
https://t.co/wBDZtaTVba
OP0038 #EULAR23 @Rheumnow https://t.co/JLdbYF49xF
David Liew drdavidliew
1 year 5 months ago
Data from combined big Scandinavian population registries looking at both RA and PsA, ILD development, & MTX exposure
Here’s the ILD risk for methotrexate.
Can we stop this MTX misinformation? No more besmirching a really useful drug for our patients #EULAR2023 OP0006 @RheumNow https://t.co/7swqAYchDC
Dr. Antoni Chan synovialjoints
1 year 5 months ago
Interstitial lung disease in RA and PSA in b/tsDMARD treated patients with MTX - there is no increased risk of developing ILD above the background risk of RA and PsA vs general population Sella Aarrestad Provan Abst#OP0006 @RheumNow https://t.co/yJsrmraeZ5
Aurelie Najm AurelieRheumo
1 year 5 months ago
Comorbidities and metabolic burden in PsA:
-Occur EARLY
-Early PsA pts > multiple comorbidities & > CV morbidity vs. age-matched early RA pts
Independent of BMI & obesity
Time to address these as part of dis pathogenesis in PsA
https://t.co/qOiGHn2eZT OP0066 #EULAR23 @Rheumnow https://t.co/lK7MbeMybO
Dr. Antoni Chan synovialjoints
1 year 5 months ago
AxSpA can be unequivocally diagnosed in the first 2 years of onset of chronic back pain with 30% definite with HLA-B27+ and imaging being the key SpA features from the SPACE cohort by
Mary Lucy Marques, Abst #OP0005 @RheumNow https://t.co/m5umD00hDf
David Liew drdavidliew
1 year 5 months ago
With all the benefits of MRI and expert rheumatologists, do our diagnoses of axSpA stick, two years later?
Overwhelmingly yes, but sometimes we do actually have to change our minds. Beware the set and forget for our clinical diagnoses
SPACE cohort #EULAR2023 OP0005 @RheumNow https://t.co/AN6XzqKlv3
Aurelie Najm AurelieRheumo
1 year 5 months ago
New benefit/risk outlook 👀 on ORAL surveillance
2 subgrps:
🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi
AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE
https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 5 months ago
#EULAR2023 Abstr #OP0048 What happened if we taper steroid in #lupus patients who are Serologically Active Clinically Quiescent? A cohort study in Asia showed:
- Tapering was NOT associated with subsequent flare
- Tapering reduced damage in those on =>5mg/day
@RheumNow https://t.co/Q6GiaSCgV6
Poster Hall